{"meshTagsMajor":["Drug Resistance, Neoplasm"],"meshTags":["Animals","Drug Resistance, Neoplasm","Humans","Male","Phenylthiohydantoin","Prostatic Neoplasms, Castration-Resistant","Receptors, Androgen","Taxoids"],"meshMinor":["Animals","Humans","Male","Phenylthiohydantoin","Prostatic Neoplasms, Castration-Resistant","Receptors, Androgen","Taxoids"],"genes":["Androgen Receptor"],"organisms":["6755"],"publicationTypes":["Comment","Letter"],"title":"Re: Robert J. van Soest, Ellen S. de Morr√©e, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.","pubmedId":"26215602"}